Robert Emil Hunger

Prof. Dr. Robert Emil Hunger

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CSChristoph Schlapbach
Christoph Schlapbach
THTanja Hänni
Tanja Hänni
NYNikhil Yawalkar
Nikhil Yawalkar
RHRobert Emil Hunger
Robert Emil Hunger

1 April 2008 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
RHRobert Emil Hunger
Robert Emil Hunger
ASA.M. Surovy
A.M. Surovy
AHA.S. Hassan
A.S. Hassan
LBL.R. Braathen
L.R. Braathen
NYN. Yawalkar
N. Yawalkar

8 December 2017 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
RTRahel Thomi
Rahel Thomi
CSChristoph Schlapbach
Christoph Schlapbach
NYNikhil Yawalkar
Nikhil Yawalkar
DSDagmar Simon
Dagmar Simon
DYDaniel Yerly
Daniel Yerly
RHRobert Emil Hunger
Robert Emil Hunger

29 August 2017 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
RTRahel Thomi
Rahel Thomi
MKMasato Kakeda
Masato Kakeda
NYNikhil Yawalkar
Nikhil Yawalkar
CSChristoph Schlapbach
Christoph Schlapbach
RHRobert Emil Hunger
Robert Emil Hunger

13 January 2014 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AGA.L. Gerber
A.L. Gerber
AMA. Münst
A. Münst
CSC. Schlapbach
C. Schlapbach
MSM. Shafighi
M. Shafighi
DKD. Kiermeir
D. Kiermeir
RHRobert Emil Hunger
Robert Emil Hunger

1 July 2008 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
UBUrs V. Buettiker
Urs V. Buettiker
NYNikhil Y. Yawalkar
Nikhil Y. Yawalkar
LBLasse R. Braathen
Lasse R. Braathen
RHRobert Emil Hunger
Robert Emil Hunger
Lentigo maligna (LM) is an in situ lesion with a 2% to 50% risk of progression to LM melanoma.1 Currently, surgery or radiotherapy is usually recommended as the primary treatment for LM. In the literature, the recurrence rates reported for radiotherapy range from 0% to 19%, with a mean recurrence rate of approximately 7%; in addition, radiotherapy carries the risk of causing chronic radiodermatitis or radiation-induced malignant neoplasm.2 A margin-controlled excision using “slow Mohs” (rush permanent sections) and Mohs micrographic surgery has the lowest recurrence rate, perhaps as low as 3%.3